Hyponatremia Is a Powerful Predictor of Poor Prognosis in Left Ventricular Assist Device Patients

From the *Department of Medicine, Division of Cardiology, Northwestern University, Chicago, Illinois

†Clinical Trials Unit, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Chicago, Illinois

‡Department of Surgery, Division of Cardiac Surgery, Northwestern University, Chicago, Illinois

§Department of Medicine, Division of Cardiology, University of Texas at San Antonio, San Antonio, Texas.

Submitted for consideration March 2021; accepted for publication in revised form January 2022.

Disclosure: K.G. is on Speakers Bureau for Abbott. J.E.W. is a Consultant for Amgen, Boehringer Ingelheim, and Scientific Advisory Board Member for Cytokinetics; E.E.V. is on Speakers Bureau for Abiomed. F.A. is a Consultant for Amgen. A.S.A. is a Consultant for Edwards Lifesciences and Pfizer. D.T.P. is a Consultant for Abbott, Medtronic, and Abiomed. J.D.R. is a Consultant for Abbott and Medtronic. For the remaining authors, there are no conflicts of interest.

Correspondence: Anjan Tibrewala, MD, MS, Division of Cardiology, Northwestern University, 660 N. St. Clair St., Suite 600, Chicago, IL 60611. E-mail: [email protected]

留言 (0)

沒有登入
gif